Compare Onto Innovation (ONTO) vs 10X Genomics Inc (TXG) Price & Performance

ONTO Innovation trades at $281.11, up 4.89% today, with strong analyst support (12 buy ratings, 0 hold/sell) and a $392.50 consensus price target suggesting 39.6% upside. The stock shows mixed earnings performance with a recent Q2 2026 beat ($1.93 vs. $1.69 expected) but misses in prior quarters. Revenue growth remains solid at $1.01B in 2025, though net income margin compressed to 11.84%. Technical indicators are neutral with support at $277 and resistance at $284.

Outlook remains positive given robust AI-driven semiconductor demand and a $1.1B+ backlog, but high valuation multiples (P/E 105.28, P/S 12.44) leave little room for execution missteps. Key risks include fiduciary investigation news, insider selling, and reliance on semiconductor cycle strength. Institutional confidence is high with BlackRock's $2.08B recent investment.

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.